Drugs / MANP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05247528 | Dec 2021 → Oct 2022 | resistant hypertension | E-Star BioTech, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05247528 ↗ |
| Modality | Peptide | “Novel designer peptide to represent a pGC-A/cGMP therapeutic” NCT05247528 ↗ |
| Route | Subcutaneous | “single subcutaneous injection each morning daily.” NCT05247528 ↗ |